VivoSeq
Other

Smokeless Tobacco

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Smokeless Tobacco is an early-stage landscape with 0 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed12 · 75%
Active, not recruiting1 · 6%
Unknown status1 · 6%
Terminated1 · 6%
Recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Testing All Nations Snuff Out Smokeless (ANSOS) for Efficacy in Multi-Tribal Urban Communities
Recruiting·Lehigh University·Preclinical·NCT06566703·384 enrolled
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT03998735·55 enrolled
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
Completed·Pfizer logoPfizer·Phase 4·NCT00717093·432 enrolled
Bupropion SR for Treating Smokeless Tobacco Use
Completed·MMayo Clinic·Phase 3·NCT00414180·225 enrolled
Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Completed·MMayo Clinic·Phase 2/3·NCT01018394·81 enrolled
A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco
Completed·MMedical University of South Carolina·N/A·NCT01509586·1,236 enrolled
Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Completed·UUniversity of Minnesota·Phase 2·NCT00218296·332 enrolled
Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Completed·MMayo Clinic·Phase 3·NCT00392379·270 enrolled
Varenicline for the Treatment of Smokeless Tobacco
Completed·MMayo Clinic·N/A·NCT00813917·76 enrolled
Efficacy of Varenicline for Smokeless Tobacco Use in India
Completed·UUniversity of Pennsylvania·Phase 2·NCT01098305·237 enrolled
Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Completed·MMayo Clinic·Phase 2/3·NCT00939029·52 enrolled
Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation
Completed·OOregon Research Institute·N/A·NCT01341938·1,067 enrolled
Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00218270·138 enrolled
Nicotine Lozenge to Reduce Smokeless Tobacco Use
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00218283·100 enrolled
Metabolism of Deuterated NNN in Smokeless Tobacco Users
Terminated·UUniversity of Minnesota·Phase 1·NCT02414477·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)